Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT04414033Not ApplicableCompleted

Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer

Role: collaborator

NCT00107913Phase 2Unknown

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Role: lead

All 2 trials loaded